Lindsay Corporation reported a 53% drop in earnings per share and a 16% decline in revenue for the quarter ending February 28, 2026, with infrastructure revenue falling 58% due to a missing prior-year project. Following this, the company's stock price dropped 12.06% on April 2, 2026. Pomerantz LLP is investigating whether Lindsay and some of its executives engaged in securities fraud or other unlawful practices. Investors are advised to contact Pomerantz LLP to join the class action lawsuit if affected.
Coloplast has received FDA approval for its Titan Prime inflatable penile prosthesis (IPP), a next-generation device designed to help men with severe erectile dysfunction. The device mimics a natural erection using a durable Bioflex polymer, offering...
Hydaway Digital Corp. has appointed Angelo Valentini, a cybersecurity industry veteran and current Head of Channel Sales at Check Point Software Technologies, as a strategic advisor. Valentini will support the advancement of Hydaway's RealityChek AI ...
The global wound irrigation systems market, valued at $307.87 million in 2025, is projected to reach $430.05 million by 2035 with a CAGR of 3.55%. Growth is fueled by increasing chronic wound cases, more surgeries, and rising diabetes and obesity rat...
ScottsMiracle-Gro reaffirmed its fiscal 2026 guidance, expecting low single-digit sales growth and a gross margin of at least 32%. The company reported a 1% increase in year-to-date branded consumer sales and has locked 90% of its commodities costs, ...
Ulta Beauty reported first-quarter fiscal 2026 earnings of $7.74 per share, surpassing analyst estimates of $6.86, with revenue rising 11.1% year-over-year to $3.16 billion. The company saw growth across fragrance, haircare, makeup, and skincare cate...
